HCPCS Code Applications and Approvals: July 2026
Quarterly archive · CMS Level II HCPCS27 coding decisions from the First Quarter 2026 CMS cycle
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the First Quarter 2026 coding cycle, which took effect July 1, 2026.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
July 2026
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| A9574 | FERABRIGHT Injection, ferumoxytol, 1 mg | Azurity Pharmaceuticals Inc. Intravenous | — | Establish | |
| C9309 | ITVISMA Injection, onasemnogene abeparvovec-brve, per treatment | Novartis Pharmaceuticals Corporation Intrathecal | Replaced byJ3405 | Discontinue | |
| J0528 | CONTEPO 505(b)(2) Injection, fosfomycin disodium, 20 mg | Meitheal Pharmaceuticals, Inc. Intravenous | — | Establish | |
| J1289 | YARTEMLEA Injection, narsoplimab-wuug, 1 mg | Omeros Corporation Intravenous | — | Establish | |
| J1553 | YIMMUGO Injection, immune globulin (yimmugo), 100 mg | Kedrion Biopharma, Inc. Intravenous | — | Establish | |
| J1569 | GAMMAGARD LIQUID ERC Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg | Takeda Pharmaceuticals Intravenous/Subcutaneous | — | Revise | |
| J1577 | QIVIGY Injection, immune globulin (qivigy), 100 mg | Kedrion Biopharma, Inc. Intravenous | — | Establish | |
| J2361 | Exdensur Injection, depemokimab-ulaa, 1 mg | GSK Subcutaneous | — | Establish | |
| J2374 | IOPIDINE Apraclonidine hydrochloride ophthalmic, 1% solution, 0.1 ml | Harrow Inc. Ophthalmic | — | Establish | |
| J2787 | Riboflavin 5'-Phosphate (Photrexa Viscous/Photrexa) 505(b)(2) Riboflavin 5'-phosphate, ophthalmic solution (photrexa viscous/photrexa), up to 3 ml | Glaukos Ophthalmic | — | Revise | |
| J2789 | Epioxa HD/Epioxa 505(b)(2) Riboflavin 5'-phosphate, ophthalmic solution (epioxa hd/epioxa), up to 2 ml | Glaukos Ophthalmic | — | Establish | |
| J3375 | TYZAVAN 505(b)(2) Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mg | Hikma Pharmaceuticals USA Inc. Intravenous | — | Revise | |
| J3386 | WASKYRA Injection, etuvetidigene autotemcel, per treatment | Fondazione Telethon Intravenous | — | Establish | |
| J3405 | ITVISMA Injection, onasemnogene abeparvovec-brve, per treatment | Novartis Pharmaceuticals Corporation Intrathecal | ReplacesC9309 | Establish | |
| J7176 | FESILTY Injection, human fibrinogen - chmt (fesilty), 1 mg | Grifols Therapeutics, LLC Intravenous | — | Establish | |
| J9053 | Blenrep Injection, belantamab mafodotin-blmf, 0.1 mg | GSK Intravenous | — | Establish | |
| J9062 | RYBREVANT FASPRO Injection, amivantamab 5 mg and hyaluronidase-lpuj | Johnson & Johnson Health Care Systems Inc. Subcutaneous | — | Establish | |
| J9232 | Docetaxel (Hospira) 505(b)(2) Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg | Pfizer/Hospira Intravenous | — | Establish | |
| Q0234 | Tofidence (COVID-19) Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg | Sandoz Inc. Intravenous | — | Establish | |
| Q5164 | STARJEMZA Biosimilar Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg | Hikma Pharmaceuticals Subcutaneous/Intravenous | — | Establish | |
| Q5165 | Oziltus Biosimilar Injection, denosumab-mobz (oziltus), biosimilar, 1 mg | Amneal Pharmaceuticals Subcutaneous | — | Establish | |
| Q5166 | OSVYRTI/JUBEREQ Biosimilar Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg | Accord Biopharma Subcutaneous | — | Establish | |
| Q5167 | Enoby/Xtrenbo Biosimilar Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg | Hikma Pharmaceuticals USA Inc. Subcutaneous | — | Establish | |
| Q5168 | NUFYMCO Biosimilar Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg | Bioeq AG Intravitreal | — | Establish | |
| Q5169 | Armlupeg Biosimilar Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg | Valorum Biologics LLC Subcutaneous | — | Establish | |
| Q5170 | EYDENZELT Biosimilar Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg | Celltrion USA, Inc. Intravitreal | — | Establish | |
| Q5171 | Boncresa Biosimilar Injection, denosumab-mobz (boncresa), biosimilar, 1 mg | Amneal Pharmaceuticals Subcutaneous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, First Quarter 2026 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
